Antimicrobial dosing considerations in obese adult patients: Insights from the society of infectious diseases pharmacists

Pharmacotherapy

Volumn 27, Issue 8, 2007, Pages 1081-1091

  Pai, Manjunath P ^a   Bearden, David T ^b  

^a UNIVERSITY OF NEW MEXICO   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

Antimicrobials; Dosing; Obesity; Pharmacokinetics

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; CEFAZOLIN; CEFIXIME; CEFOTAXIME; CEFOTIAM; CEFPODOXIME; CEFTRIAXONE; CIPROFLOXACIN; CREATININE; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ERTAPENEM; FLUCONAZOLE; FLUCYTOSINE; GARENOXACIN; GENTAMICIN; ISONIAZID; LINEZOLID; MEROPENEM; MOXIFLOXACIN; NAFCILLIN; OFLOXACIN; OROSOMUCOID; PIVAMPICILLIN; STREPTOMYCIN; SULFAFURAZOLE; TELITHROMYCIN; TROVAFLOXACIN; VANCOMYCIN;

ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BODY WEIGHT; CREATININE CLEARANCE; DIABETES MELLITUS; DOSE CALCULATION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG TISSUE LEVEL; GLOMERULUS FILTRATION RATE; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; OBESITY; REVIEW; SINGLE DRUG DOSE; TISSUE DISTRIBUTION;

ANTI-INFECTIVE AGENTS; BODY WEIGHT; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; OBESITY; TISSUE DISTRIBUTION;

EID: 34547431719     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.27.8.1081     Document Type: Review

References (81)

1. World Health Organization. Obesity and overweight. Fact sheet 311. September 2006. Available from http://www.who.int/mediacentre/factsheets/fs311/ en/print.htm. Accessed December 13, 2006.
2. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006;295:1549-55.
3. Rigby N, James P. Waiting for a green light for health? Europe at the crossroads for diet and disease. International obesity task force position paper. September 11, 2002. Available from http://www.iotf.org/media/euobesity. pdf. Accessed December 13, 2006.
4. Yoon KH, Lee JH, Kim JW, et al. Epidemic obesity and type 2 diabetes in Asia. Lancet 2006;368:1681-8.
5. Falagas ME, Kompoti M. Obesity and infection. Lancet Infect Dis 2006;6:438-46.
6. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005;115:911-19.
7. Bamgbade OA, Rutter TW, Nafiu OO, Dorje P. Postoperative complications in obese and nonobese patients. World J Surg 2007;31:556-60.
8. Nasraway SA Jr, Albert M, Donnelly AM, Ruthazer R, Shikora SA, Saltzman E. Morbid obesity is an independent determinant of death among surgical critically ill patients. Crit Care Med 2006;34:964-70.
9. World Health Organization Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157-63.
10. World Health Organization. Obesity: preventing and managing the global epidemic. Report of a WHO consultation. WHO technical report series 894. Geneva, Switzerland: World Health Organization, 2000.
11. Pai MP, Paloucek FP. The origin of the "ideal" body weight equations. Ann Pharmacother 2000;34:1066-9.
12. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-10.
13. DeRyke CA, Lee SY, Kuti JL, Nicolau DP. Optimising dosing strategies of antibacterials utilizing pharmacodynamic principles: impact on the development of resistance. Drugs 2006;66:1-14.
14. Abernethy DR, Greenblatt DJ. Drug disposition in obese humans: an update. Clin Pharmacokinet 1986;11:199-213.
15. Rosell S, Belfrage E. Blood circulation in adipose tissue. Physiol Rev 1979;59:1078-104.
16. Bosma RJ, Krikken JA, Homan van der Heide JJ, de Jong PE, Navis GJ. Obesity and renal hemodynamics. Contrib Nephrol 2006;151:184-202.
17. Rea DJ, Heimbach JK, Grande JP, et al. Glomerular volume and renal histology in obese and non-obese living kidney donors. Kidney Int 2006;70:1636-41.
18. Green B, Duffull SB. What is the best size descriptor to use for pharmacokinetic studies in the obese? Br J Clin Pharmacol 2004;58:119-33.
19. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
20. Verhave JC, Fesler P, Ribstein J, du Cailar G, Mimran A. Estimation of renal function in subjects with normal serum creatinine levels: influence of age and body mass index. Am J Kidney Dis 2005;46:233-41.
21. Spinier SA, Nawarskas JJ, Boyce EG, Connors JE, Charland SL, Goldfarb S, for the Iohexol Cooperative Study Group. Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Ann Pharmacother 1998;32:1275-83.
22. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988;84:1053-60.
23. Dionne RE, Bauer LA, Gibson GA, Griffen WO Jr, Blouin RA. Estimating creatinine clearance in morbidly obese patients. Am J Hosp Pharm 1981;38:841-4.
24. Snider RD, Kruse JA, Bander JJ, Dunn GH. Accuracy of estimated creatinine clearance in obese patients with stable renal function in the intensive care unit. Pharmacotherapy 1995;15:747-53.
25. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, for the Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999;130:461-70.
26. Delanaye P, Radermecker RP, Rorive M, Depas G, Krzesinski JM. Indexing glomerular filtration rate for body surface area in obese patients is misleading: concept and example. Nephrol Dial Transplat 2005;20:2024-8.
27. 51Cr-EDTA clearance. Clin Nephrol 2004;62:97-103.
28. Cherry RA, Eachempati SR, Hydo L, Barie PS. Accuracy of short-duration creatinine clearance determinations in predicting 24-hour creatinine clearance in critically ill and injured patients. J Trauma 2002;53:267-71.
29. Liu P, Muller M, Derendorf H. Rational dosing of antibiotics: the use of plasma concentrations versus tissue concentrations. Int J Antimicrob Agents 2002;19:285-90.
30. Bjorkman S. Prediction of the volume of distribution of a drug: which tissue-plasma partition coefficients are needed? J Pharm Pharmacol 2002;54:1237-45.
31. Langer O, Muller M. Methods to assess tissue-specific distribution and metabolism of drugs. Curr Drug Metab 2004;5:463-81.
32. Burkhardt O, Brunner M, Schmidt S, Grant M, Tang Y, Derendorf H. Penetration of ertapenem into skeletal muscle and subcutaneous adipose tissue in healthy volunteers measured by in vivo microdialysis. J Antimicrob Chemother 2006;58:632-6.
33. Burkhardt O, Derendorf H, Jager D, et al. Moxifloxacin distribution in the interstitial space of infected decubitus ulcer tissue of patients with spinal cord injury measured by in vivo microdialysis. Scand J Infect Dis 2006;38:904-8.
34. Bielecka-Grzela S, Klimowicz A. Evaluation of ofloxacin penetration into the skin after a single oral dose assessed by cutaneous microdialysis. Pol J Pharmacol 2003;55:613-18.
35. Liu P, Muller M, Grant M, Obermann B, Derendorf H. Tissue penetration of cefpodoxime and cefixime in healthy subjects. J Clin Pharmacol 2005;45:564-9.
36. Buerger C, Plock N, Dehghanyar P, Joukhadar C, Kloft C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob Agents Chemother 2006;50: 2455-63.
37. Gattringer R, Urbauer E, Traunmuller F, et al. Pharmacokinetics of telithromycin in plasma and soft tissues after single-dose administration to healthy volunteers. Antimicrob Agents Chemother 2004;48:4650-3.
38. Skhirtladze K, Hutschala D, Fleck T, et al. Impaired target site penetration of vancomycin in diabetic patients following cardiac surgery. Antimicrob Agents Chemother 2006;50: 1372-5.
39. Hull JH, Sarubbi FA. Gentamicin serum concentrations: pharmacokinetic predictions. Ann Intern Med 1976;85:183-9.
40. Schwartz SN, Pazin GJ, Lyon JA, Monto H, Pasculle AW. A controlled investigation of the pharmacokinetics of gentamicin and tobramycin in obese subjects. J Infect Dis 1978;138: 499-505.
41. Korsager S. Administration of gentamicin to obese patients. Int J Clin Pharmacol Ther Toxicol 1980;18:549-53.
42. Sketris I, Lesar T, Zaske DE, Cipolle RJ. Effect of obesity on gentamicin pharmacokinetics. J Clin Pharmacol 1981;2: 288-93.
43. Bauer LA, Edwards WA, Dellinger EP, Simonowitz DA. Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients. Eur J Clin Pharmacol 1983;24:643-7.
44. Traynor AM, Nafziger AN, Bertino JS. Aminoglycoside dosing weight correction factors for patients of various body sizes. Antimicrob Agents Chemother 1995;39:545-8.
45. Leader WG, Tsubaki T, Chandler MH. Creatinine clearance estimates for predicting gentamicin pharmacokinetic values in obese patients. Am J Hosp Pharm 1994;51:2125-30.
46. Blouin RA, Mann HJ, Griffen WO, Bauer LA, Record KE. Tobramycin pharmacokinetics in morbidly obese patients. Clin Pharmacol Ther 1979;26:508-12.
47. Bauer LA, Blouin RA, Griffen WO, Record KE, Bell RM. Amikacin pharmacokinetics in morbidly obese patients. Am J Hosp Pharm 1980;37:519-22.
48. Blouin RA, Brouwer KL, Record KE, Griffin WO, Plezia PM, John W. Amikacin pharmacokinetics in morbidly obese patients undergoing gastric bypass surgery. Clin Pharm 1985;4:70-2.
49. Blouin RA, Bauer LA, Miller DD, Record KE, Griffen WO. Vancomycin pharmacokinetics in normal and morbidly obese subjects. Antimicrob Agents Chemother 1982;21:575-80.
50. Vance Bryan K, Guay DR, Gilliland SS, Rodvold KA, Rotschafer JC. Effect of obesity on vancomycin pharmacokinetic parameters as determined by using a Bayesian forecasting technique. Antimicrob Agents Chemother 1993;37:436-40.
51. Ducharme MP, Slaughter RL, Edwards DJ. Vancomycin pharmacokinetics in a patient population: effect of age, gender, and body weight. Ther Drug Monit 1994;16:513-18.
52. Bauer LA, Black DJ, Lill JS. Vancomycin dosing in morbidly obese patients. Eur J Clin Pharmacol 1998;54:621-5.
53. Penzak SR, Gubbins PO, Rodvold KA, Hickerson SL. Therapeutic drug monitoring of vancomycin in a morbidly obese patient. Ther Drug Monit 1998;20:261-5.
54. Chiba K, Tsuchiya M, Kato J, Ochi K, Kawa Z, Ishizaki T. Cefotiam disposition in markedly obese athlete patients, Japanese sumo wrestlers. Antimicrob Agents Chemother 1989;33:1188-92.
55. Yost RL, Derendorf H. Disposition of cefotaxime and its desacetyl metabolite in morbidly obese male and female subjects. Ther Drug Monit 1986;8:189-94.
56. Mann HJ, Buchwald H. Cefamandole distribution in serum, adipose tissue, and wound drainage in morbidly obese patients. Drug Intell Clin Pharm 1986;20:869-73.
57. Lovering AM, Walsh TR, Bannister GC, MacGowan AP. The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone. J Antimicrob Chemother 2001;47: 483-6.
58. Forse RA, Karam B, MacLean LD, Christou NV. Antibiotic prophylaxis for surgery in morbidly obese patients. Surgery 1989;106:750-7.
59. Pories WJ, van Rij AM, Burlingham BT, Fulghum RS, Meelheim D. Prophylactic cefazolin in gastric bypass surgery. Surgery 1981;90:426-32.
60. Mehta U, Malone M, Alger S. Cefazolin use in clinically severe obese patients undergoing gastric restrictive surgery. Ann Pharmacother 1995;29:935-6.
61. Yuk J, Nightingale CH, Sweeney K, Levitz RE, Quintiliani R. Pharmacokinetics of nafcillin in obesity. J Infect Dis 1988;157:1088-9.
62. Kampmann JP, Klein H, Lumholtz B, Molholm Hansen JE. Ampicillin and propylthiouracil pharmacokinetics in intestinal bypass patients followed up to a year after operation. Clin Pharmacokinet 1984;9:168-76.
63. Chen M, Nafziger AN, Drusano GL, Ma L, Bertino JS Jr. Comparative pharmacokinetics and pharmacodynamic target attainment of ertapenem in normal-weight, obese, and extremely obese adults. Antimicrob Agents Chemother 2006;50:1222-7.
64. Bearden DT, Earle SB, McConnell DB, Belle DJ, Kohlhepp SJ. Pharmacokinetics of meropenem in extreme obesity [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005:2.
65. Allard S, Kinzig M, Boivin G, Sorgel F, LeBel M. Intravenous ciprofloxacin disposition in obesity. Clin Pharmacol Ther 1993;54:368-73.
66. Caldwell JB, Nilsen AK. Intravenous ciprofloxacin dosing in a morbidly obese patient. Ann Pharmacother 1994;28:806.
67. Hollenstein UM, Brunner M, Schmid R, Muller M. Soft tissue concentrations of ciprofloxacin in obese and lean subjects following weight-adjusted dosing. Int J Obes Relat Metab Disord 2001;25:354-8.
68. Pai MP, Bordley J, Amsden GW. Plasma pharmacokinetics and tissue penetration of alatrofloxacin in morbidly obese individuals. Clin Drug Invest 2001:21;175-81.
69. Van Wart S, Phillips L, Ludwig EA, et al. Population pharmacokinetics and pharmacodynamics of garenoxacin in patients with community-acquired respiratory tract infections. Antimicrob Agents Chemother 2004;48:4766-77.
70. Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005;45:48-56.
71. Pai MP, Norenberg JP, Anderson T, et al. Daptomycin pharmacokinetics in morbidly obese subjects [abstract]. In: Program and abstracts of the 46th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2006:A-1947.
72. Schriever CA, Fernandez C, Rodvold KA, Danziger LH. Daptomycin: a novel cyclic lipopeptide antimicrobial. Am J Health-Syst Pharm 2005;62:1145-58.
73. Meagher AK, Forrest A, Rayner CR, Birmingham MC, Schentag JJ. Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother 2003;47:548-53.
74. Stein GE, Schooley SL, Peloquin CA, et al. Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005;39:427-32.
75. Mersfelder TL, Smith CL. Linezolid pharmacokinetics in an obese patient. Am J Health-Syst Pharm 2005;62:464, 467.
76. Lefebvre P, Rey J, Morganroth J, Geary W, Montay G. Open, comparative, study of the safety of a single dose of quinupristin/dalfopristin (Q/D, RP 59500) in obese and in non-obese male subjects [abstract and poster]. Presented at the 20th international congress of chemotherapy, Sydney, Australia, June 29-July 3, 1997.
77. Cohen LG, DiBiasio A, Lisco SJ, Hurford WE. Fluconazole serum concentrations and pharmacokinetics in an obese patient. Pharmacotherapy 1997;17:1023-6.
78. Gillum JG, Johnson M, Lavoie S, Venitz J. Flucytosine dosing in an obese patient with extrameningeal cryptococcal infection. Pharmacotherapy 1995;15:251-3.
79. Groll AH, Mickiene D, Piscitelli SC, Walsh TJ. Distribution of lipid formulations of amphotericin B into bone marrow and fat tissue in rabbits. Antimicrob Agents Chemother 2000;44:408-10.
80. Garrett ER, Suverkrup RS, Eberst K, Yost RL, O'Leary JP. Surgically affected sulfisoxazole pharmacokinetics in the morbidly obese. Biopharm Drug Dispos 1981;2:329-65.
81. Geiseler PJ, Manis RD Jr, Maddux MS. Dosage of anti-tuberculous drugs in obese patients. Am Rev Respir Dis 1985;131:944-6.